CYP24A1 and prostate carcinoma: Our results are in agreement with in vivo studies in which orthotopic prostate cancer xenograft growth was markedly reduced in mice exposed to calcitriol and CYP24A1 shRNA or to a combination of calcitriol and ketoconazole/dexamethasone [18, 32].